Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 5, 2021Cochrane libraryOpen Access

Remdesivir for the treatment of COVID-19

View Full Paper
Ask AI
Bookmark
Share

Authors

KAKelly AnsemsFGFelicitas GrundeisKDKarolina Dahms

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ansems et al. (2021) studied this question.

synapsesocial.com/papers/69d80fb95c3030ff03d18f31https://doi.org/10.1002/14651858.cd014962
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study2020 · 2,968 citations
  2. 2Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review2020 · 155 citations
  3. 3Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial2021 · 15 citations
  4. 4Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care2020 · 171 citations
  5. 5Prevalence of Asymptomatic SARS-CoV-2 Infection2020 · 2,483 citations